RMI 9563的免疫药理学和抗炎特性，特别涉及其对补体系统的作用。

The immunopharmacologic and anti-inflammatory properties of RMI 9563 with special reference to its effect on the complement system.

作者信息

Megel H, Raychaudhuri A, Bayer M, Beaver T H

出版信息

Agents Actions. 1978 Apr;8(3):218-28. doi: 10.1007/BF01966607.

DOI:10.1007/BF01966607

Abstract

The immunopharmacology of RMI 9563 - bis[3-(diethylamino)propyl]fluoranthene-3,9-dicarboxylate dihydrochloride--has been described. The compound, when given parenterally, inhibited several cell-mediated immune responses (EAE, tuberculin skin reaction, adjuvant arthritis) in rats, enhanced IgM and IgG antibody-producing cells in mice, and displayed anti-inflammatory activity in several models (carrageenan paw edema, adjuvant arthritis, direct passive Arthus reaction--a model of inflammation that is immunologically induced and complement-dependent). RMI 9563 suppressed the activation of complement in vitro by the selective inhibition of C1 esterase.

摘要

已对RMI 9563（双[3 -（二乙氨基）丙基]荧蒽-3,9 -二羧酸二盐酸盐）的免疫药理学进行了描述。该化合物经肠胃外给药时，可抑制大鼠的多种细胞介导的免疫反应（实验性自身免疫性脑脊髓炎、结核菌素皮肤反应、佐剂性关节炎），增强小鼠中产生IgM和IgG抗体的细胞，并在多种模型（角叉菜胶足肿胀、佐剂性关节炎、直接被动阿瑟斯反应——一种免疫诱导且补体依赖的炎症模型）中表现出抗炎活性。RMI 9563通过选择性抑制C1酯酶在体外抑制补体的激活。